<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cardiovasc Magn Reson</journal-id><journal-id journal-id-type="iso-abbrev">J Cardiovasc Magn Reson</journal-id><journal-title-group><journal-title>Journal of Cardiovascular Magnetic Resonance</journal-title></journal-title-group><issn pub-type="ppub">1097-6647</issn><issn pub-type="epub">1532-429X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5032294</article-id><article-id pub-id-type="publisher-id">4999</article-id><article-id pub-id-type="doi">10.1186/1532-429X-18-S1-P75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Rationale and design of the Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multi-centre, randomized controlled trial of diagnostic strategies for suspected coronary heart disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ripley</surname><given-names>David P</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Everett</surname><given-names>Colin C</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bijsterveld</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sculpher</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>McCann</surname><given-names>Gerry P</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Berry</surname><given-names>Colin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Plein</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Greenwood</surname><given-names>John P</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>grid.9909.90000000419368403Multidisciplinary Cardiovascular Research Centre (MCRC) &#x00026; Leeds Institute of Cardiovascular and Metabolic Medicine, University Of Leeds, Leeds, UK </aff><aff id="Aff2"><label>2</label>grid.9909.90000000419368403Clinical Trials Research Unit, University of Leeds, Leeds, UK </aff><aff id="Aff3"><label>3</label>grid.5685.e0000000419369668Centre for Health Economics, University of York, York, UK </aff><aff id="Aff4"><label>4</label>grid.9918.90000000419368411Department of Cardiovascular Sciences, University of Leicester, Leicester, UK </aff><aff id="Aff5"><label>5</label>grid.8756.c000000012193314XBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>18</volume><issue>Suppl 1</issue><issue-sponsor>Publication of this supplement was funded by the Society for Cardiovascular Magnetic Resonance.</issue-sponsor><elocation-id>P75</elocation-id><permissions><copyright-statement>&#x000a9; Ripley et al. 2016</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><conference><conf-name>19th Annual SCMR Scientific Sessions</conf-name><conf-loc>Los Angeles, CA, USA</conf-loc><conf-date>27-30 January 2016</conf-date><string-conf><uri>http://www.scmr2016.org</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>A number of investigative strategies exist for the diagnosis of coronary heart disease (CHD). Despite the widespread availability of non-invasive imaging, invasive angiography is commonly used early in the diagnostic pathway. Consequently, approximately 60% of angiograms reveal no evidence of obstructive coronary disease. Reducing unnecessary angiography has potential financial savings and avoids exposing the patient to unnecessary risk. There are no large scale comparative effectiveness trials of the different diagnostic strategies recommended in international guidelines and none that have evaluated the safety and efficacy of cardiovascular magnetic resonance (CMR).</p></sec><sec id="Sec2"><title>Methods</title><p>CE-MARC 2 is a prospective, multi-centre, 3-arm parallel group, randomized controlled trial of patients with suspected CHD (pre-test likelihood 10-90%) requiring further investigation. 1200 patients will be randomized on a 2:2:1 basis to receive 3.0 Tesla CMR-guided care, single photon emission computed tomography (SPECT) guided care (according to ACC/AHA appropriate-use criteria) or National Institute for Health and Care Excellence guidelines-based management. The primary (efficacy) endpoint is the occurrence of unnecessary angiography as defined by a normal (&#x0003e;0.8) invasive fractional flow reserve. Safety of each strategy will be assessed by 3-year major adverse cardiovascular event rates. Cost effectiveness and health related quality of life (HRQoL) measures will be performed.</p></sec><sec id="Sec3"><title>Results</title><p>The CE-MARC 2 trial will provide comparative efficacy and safety evidence for three different strategies of investigating patient with suspected CHD, with the intension of reducing unnecessary invasive angiography rates.</p></sec><sec id="Sec4"><title>Conclusions</title><p>Evaluation of these management strategies has the potential to improve patient care, HRQoL and the cost effectiveness of CHD investigation.<fig id="Fig1"><label>Figure 1</label><caption><p><bold>CE-MARC 2 study flow diagram illustrating randomization, investigative strategy and study end-points</bold>.</p></caption><graphic xlink:href="12968_2016_Article_4999_Fig1_HTML" id="d30e315"/></fig></p></sec></body></article>